Cargando…

Pharmacological characterization of potent and selective Na(V)1.7 inhibitors engineered from Chilobrachys jingzhao tarantula venom peptide JzTx-V

Identification of voltage-gated sodium channel Na(V)1.7 inhibitors for chronic pain therapeutic development is an area of vigorous pursuit. In an effort to identify more potent leads compared to our previously reported GpTx-1 peptide series, electrophysiology screening of fractionated tarantula veno...

Descripción completa

Detalles Bibliográficos
Autores principales: Moyer, Bryan D., Murray, Justin K., Ligutti, Joseph, Andrews, Kristin, Favreau, Philippe, Jordan, John B., Lee, Josie H., Liu, Dong, Long, Jason, Sham, Kelvin, Shi, Licheng, Stöcklin, Reto, Wu, Bin, Yin, Ruoyuan, Yu, Violeta, Zou, Anruo, Biswas, Kaustav, Miranda, Les P.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5933747/
https://www.ncbi.nlm.nih.gov/pubmed/29723257
http://dx.doi.org/10.1371/journal.pone.0196791
_version_ 1783320001348894720
author Moyer, Bryan D.
Murray, Justin K.
Ligutti, Joseph
Andrews, Kristin
Favreau, Philippe
Jordan, John B.
Lee, Josie H.
Liu, Dong
Long, Jason
Sham, Kelvin
Shi, Licheng
Stöcklin, Reto
Wu, Bin
Yin, Ruoyuan
Yu, Violeta
Zou, Anruo
Biswas, Kaustav
Miranda, Les P.
author_facet Moyer, Bryan D.
Murray, Justin K.
Ligutti, Joseph
Andrews, Kristin
Favreau, Philippe
Jordan, John B.
Lee, Josie H.
Liu, Dong
Long, Jason
Sham, Kelvin
Shi, Licheng
Stöcklin, Reto
Wu, Bin
Yin, Ruoyuan
Yu, Violeta
Zou, Anruo
Biswas, Kaustav
Miranda, Les P.
author_sort Moyer, Bryan D.
collection PubMed
description Identification of voltage-gated sodium channel Na(V)1.7 inhibitors for chronic pain therapeutic development is an area of vigorous pursuit. In an effort to identify more potent leads compared to our previously reported GpTx-1 peptide series, electrophysiology screening of fractionated tarantula venom discovered the Na(V)1.7 inhibitory peptide JzTx-V from the Chinese earth tiger tarantula Chilobrachys jingzhao. The parent peptide displayed nominal selectivity over the skeletal muscle Na(V)1.4 channel. Attribute-based positional scan analoging identified a key Ile28Glu mutation that improved Na(V)1.4 selectivity over 100-fold, and further optimization yielded the potent and selective peptide leads AM-8145 and AM-0422. NMR analyses revealed that the Ile28Glu substitution changed peptide conformation, pointing to a structural rationale for the selectivity gains. AM-8145 and AM-0422 as well as GpTx-1 and HwTx-IV competed for ProTx-II binding in HEK293 cells expressing human Na(V)1.7, suggesting that these Na(V)1.7 inhibitory peptides interact with a similar binding site. AM-8145 potently blocked native tetrodotoxin-sensitive (TTX-S) channels in mouse dorsal root ganglia (DRG) neurons, exhibited 30- to 120-fold selectivity over other human TTX-S channels and exhibited over 1,000-fold selectivity over other human tetrodotoxin-resistant (TTX-R) channels. Leveraging Na(V)1.7-Na(V)1.5 chimeras containing various voltage-sensor and pore regions, AM-8145 mapped to the second voltage-sensor domain of Na(V)1.7. AM-0422, but not the inactive peptide analog AM-8374, dose-dependently blocked capsaicin-induced DRG neuron action potential firing using a multi-electrode array readout and mechanically-induced C-fiber spiking in a saphenous skin-nerve preparation. Collectively, AM-8145 and AM-0422 represent potent, new engineered Na(V)1.7 inhibitory peptides derived from the JzTx-V scaffold with improved Na(V) selectivity and biological activity in blocking action potential firing in both DRG neurons and C-fibers.
format Online
Article
Text
id pubmed-5933747
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-59337472018-05-18 Pharmacological characterization of potent and selective Na(V)1.7 inhibitors engineered from Chilobrachys jingzhao tarantula venom peptide JzTx-V Moyer, Bryan D. Murray, Justin K. Ligutti, Joseph Andrews, Kristin Favreau, Philippe Jordan, John B. Lee, Josie H. Liu, Dong Long, Jason Sham, Kelvin Shi, Licheng Stöcklin, Reto Wu, Bin Yin, Ruoyuan Yu, Violeta Zou, Anruo Biswas, Kaustav Miranda, Les P. PLoS One Research Article Identification of voltage-gated sodium channel Na(V)1.7 inhibitors for chronic pain therapeutic development is an area of vigorous pursuit. In an effort to identify more potent leads compared to our previously reported GpTx-1 peptide series, electrophysiology screening of fractionated tarantula venom discovered the Na(V)1.7 inhibitory peptide JzTx-V from the Chinese earth tiger tarantula Chilobrachys jingzhao. The parent peptide displayed nominal selectivity over the skeletal muscle Na(V)1.4 channel. Attribute-based positional scan analoging identified a key Ile28Glu mutation that improved Na(V)1.4 selectivity over 100-fold, and further optimization yielded the potent and selective peptide leads AM-8145 and AM-0422. NMR analyses revealed that the Ile28Glu substitution changed peptide conformation, pointing to a structural rationale for the selectivity gains. AM-8145 and AM-0422 as well as GpTx-1 and HwTx-IV competed for ProTx-II binding in HEK293 cells expressing human Na(V)1.7, suggesting that these Na(V)1.7 inhibitory peptides interact with a similar binding site. AM-8145 potently blocked native tetrodotoxin-sensitive (TTX-S) channels in mouse dorsal root ganglia (DRG) neurons, exhibited 30- to 120-fold selectivity over other human TTX-S channels and exhibited over 1,000-fold selectivity over other human tetrodotoxin-resistant (TTX-R) channels. Leveraging Na(V)1.7-Na(V)1.5 chimeras containing various voltage-sensor and pore regions, AM-8145 mapped to the second voltage-sensor domain of Na(V)1.7. AM-0422, but not the inactive peptide analog AM-8374, dose-dependently blocked capsaicin-induced DRG neuron action potential firing using a multi-electrode array readout and mechanically-induced C-fiber spiking in a saphenous skin-nerve preparation. Collectively, AM-8145 and AM-0422 represent potent, new engineered Na(V)1.7 inhibitory peptides derived from the JzTx-V scaffold with improved Na(V) selectivity and biological activity in blocking action potential firing in both DRG neurons and C-fibers. Public Library of Science 2018-05-03 /pmc/articles/PMC5933747/ /pubmed/29723257 http://dx.doi.org/10.1371/journal.pone.0196791 Text en © 2018 Moyer et al http://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Research Article
Moyer, Bryan D.
Murray, Justin K.
Ligutti, Joseph
Andrews, Kristin
Favreau, Philippe
Jordan, John B.
Lee, Josie H.
Liu, Dong
Long, Jason
Sham, Kelvin
Shi, Licheng
Stöcklin, Reto
Wu, Bin
Yin, Ruoyuan
Yu, Violeta
Zou, Anruo
Biswas, Kaustav
Miranda, Les P.
Pharmacological characterization of potent and selective Na(V)1.7 inhibitors engineered from Chilobrachys jingzhao tarantula venom peptide JzTx-V
title Pharmacological characterization of potent and selective Na(V)1.7 inhibitors engineered from Chilobrachys jingzhao tarantula venom peptide JzTx-V
title_full Pharmacological characterization of potent and selective Na(V)1.7 inhibitors engineered from Chilobrachys jingzhao tarantula venom peptide JzTx-V
title_fullStr Pharmacological characterization of potent and selective Na(V)1.7 inhibitors engineered from Chilobrachys jingzhao tarantula venom peptide JzTx-V
title_full_unstemmed Pharmacological characterization of potent and selective Na(V)1.7 inhibitors engineered from Chilobrachys jingzhao tarantula venom peptide JzTx-V
title_short Pharmacological characterization of potent and selective Na(V)1.7 inhibitors engineered from Chilobrachys jingzhao tarantula venom peptide JzTx-V
title_sort pharmacological characterization of potent and selective na(v)1.7 inhibitors engineered from chilobrachys jingzhao tarantula venom peptide jztx-v
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5933747/
https://www.ncbi.nlm.nih.gov/pubmed/29723257
http://dx.doi.org/10.1371/journal.pone.0196791
work_keys_str_mv AT moyerbryand pharmacologicalcharacterizationofpotentandselectivenav17inhibitorsengineeredfromchilobrachysjingzhaotarantulavenompeptidejztxv
AT murrayjustink pharmacologicalcharacterizationofpotentandselectivenav17inhibitorsengineeredfromchilobrachysjingzhaotarantulavenompeptidejztxv
AT liguttijoseph pharmacologicalcharacterizationofpotentandselectivenav17inhibitorsengineeredfromchilobrachysjingzhaotarantulavenompeptidejztxv
AT andrewskristin pharmacologicalcharacterizationofpotentandselectivenav17inhibitorsengineeredfromchilobrachysjingzhaotarantulavenompeptidejztxv
AT favreauphilippe pharmacologicalcharacterizationofpotentandselectivenav17inhibitorsengineeredfromchilobrachysjingzhaotarantulavenompeptidejztxv
AT jordanjohnb pharmacologicalcharacterizationofpotentandselectivenav17inhibitorsengineeredfromchilobrachysjingzhaotarantulavenompeptidejztxv
AT leejosieh pharmacologicalcharacterizationofpotentandselectivenav17inhibitorsengineeredfromchilobrachysjingzhaotarantulavenompeptidejztxv
AT liudong pharmacologicalcharacterizationofpotentandselectivenav17inhibitorsengineeredfromchilobrachysjingzhaotarantulavenompeptidejztxv
AT longjason pharmacologicalcharacterizationofpotentandselectivenav17inhibitorsengineeredfromchilobrachysjingzhaotarantulavenompeptidejztxv
AT shamkelvin pharmacologicalcharacterizationofpotentandselectivenav17inhibitorsengineeredfromchilobrachysjingzhaotarantulavenompeptidejztxv
AT shilicheng pharmacologicalcharacterizationofpotentandselectivenav17inhibitorsengineeredfromchilobrachysjingzhaotarantulavenompeptidejztxv
AT stocklinreto pharmacologicalcharacterizationofpotentandselectivenav17inhibitorsengineeredfromchilobrachysjingzhaotarantulavenompeptidejztxv
AT wubin pharmacologicalcharacterizationofpotentandselectivenav17inhibitorsengineeredfromchilobrachysjingzhaotarantulavenompeptidejztxv
AT yinruoyuan pharmacologicalcharacterizationofpotentandselectivenav17inhibitorsengineeredfromchilobrachysjingzhaotarantulavenompeptidejztxv
AT yuvioleta pharmacologicalcharacterizationofpotentandselectivenav17inhibitorsengineeredfromchilobrachysjingzhaotarantulavenompeptidejztxv
AT zouanruo pharmacologicalcharacterizationofpotentandselectivenav17inhibitorsengineeredfromchilobrachysjingzhaotarantulavenompeptidejztxv
AT biswaskaustav pharmacologicalcharacterizationofpotentandselectivenav17inhibitorsengineeredfromchilobrachysjingzhaotarantulavenompeptidejztxv
AT mirandalesp pharmacologicalcharacterizationofpotentandselectivenav17inhibitorsengineeredfromchilobrachysjingzhaotarantulavenompeptidejztxv